INTRODUCTION

Freezing of gait (FOG) is a major disabling motor symptom that affects the daily quality of life of Parkinson’s disease (PD) patients. Prevalence of FOG increases with longer disease duration (Kalia & Lang, 2015). It has been reported that 81% of PD patients experienced FOG after a disease duration of 20 years (Hely, Reid, Adena, Halliday, & Morris, 2008). FOG in PD patients is the main cause of falling, fracture risk, and activities of daily living disability (Okuma, 2014; Okuma, Silva de Lima, Fukae, Bloem, & Snijders, 2018).

The pathogenesis of FOG is complicated and involves multiple mechanisms, including disordered limbic system and cognitive functions regulated by the basal ganglia, supplementary motor area, and cerebral cortex (Iseki et al., 2015; Okuma, 2014; Snijders et al., 2016; Teramoto, Morita, Ninomiya, Shiota, & Kamei, 2014). The association of FOG with these systems has not yet been investigated in detail.

The accurate detection of FOG is often difficult in daily clinical practice, as FOG is not often observed in outpatients, because PD patients always come to hospital in the “on” state, and some patients may not completely understand FOG well enough to ask about it. Recently, the detection of FOG by wearable devices has been attempted (Silva de Lima et al., 2017). However, this technology is still in the research stage and is not used in clinical practice. On the other hand, evaluation of FOG via questionnaire is simple and less burdensome for patients (Barthel, Mallia, Debü, Bloem, & Ferraye, 2016).
and specificity have been reported using the New Freezing of Gait Questionnaire (NFOG-Q), which uses a video that explains FOG (Barthel et al., 2016; Nieuwboer et al., 2009). We hypothesized that the number of PD patients with subjectively reported FOG in everyday life is more than expected and that investigation of the differences in associated factors between objectively detected FOG and subjectively reported FOG would provide some clues for elucidating the mechanisms of FOG in PD patients. This study had the following two aims. First, to identify FOG in daily practice by a clinical examination and a questionnaire. Second, to compare the clinical features (such as demographic characteristics, motor symptoms, nonmotor symptoms, cognitive function, and medication use) between FOG identified by a clinical examination and FOG identified by a questionnaire.

2 | METHODS

2.1 | Subjects

We recruited consecutive patients with sporadic PD in the Department of Neurology at Tottori University Hospital between July 2014 and April 2017. The diagnosis of PD was confirmed according to the United Kingdom PD Brain Bank. Regardless of the presence or absence of FOG, we investigated all of the patients who consented to our study by questionnaire and examination. Patients who were unable to walk or who had undergone functional stereotactic surgery for PD were excluded, but PD patients with dementia were investigated via responses from their families. The study was approved by the Tottori University Committee for Medical Research Ethics and followed the principles outlined in the Declaration of Helsinki.

2.2 | Self-reported FOG

In order to detect self-reported FOG (SFOG), we used a self-administered questionnaire (NFOG-Q) (Nieuwboer et al., 2009). The range of NFOG-Q scores was 0–28; we defined an NFOG-Q score ≥ 1 point as SFOG-positive.

2.3 | Clinically observed FOG

After patients completed the NFOG-Q, we performed physical examinations to assess clinically observed FOG (CFOG). We instructed patients to walk naturally through a fixed course. We created a few situations in the course that are reported to have a high probability of FOG occurrence (Nutt et al., 2011; Schaafsma et al., 2003; Snijders, Haaxma, Hagen, Munneke, & Bloem, 2012). We checked for the presence or absence of FOG at 5 points, with reference to the previous study of Schaafsma et al. (2003): (a) start hesitation, when freezing was detected as the patient initiated walking; (b) straight gait, (c) apparent hesitation in a narrow space, when FOG was noted when the patient passed through a narrow space (d) turning hesitation, when the patient’s feet appeared to become stuck whilst making a turn, and (e) destination hesitation, when the patient’s feet appeared to freeze as the patient approached a chair (Figure 1). We defined CFOG as “a brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk” during the patient’s walk through the course (Nutt et al., 2011).

2.4 | Assessment of motor and nonmotor symptoms

Motor symptoms were evaluated using the Unified Parkinson’s Disease Rating Scale (UPDRS), Part 3. We classified Tremor, Akinesia, Rigidity, and postural instability gait difficulty (PIGD) using the results of UPDRS Part 3, in which Items 20 and 21 were for tremor, Item 22 was for rigidity, Items 23–26 and 31 were for bradykinesia, and Items 27–30 were for PIGD (Zuo et al., 2017). In addition, to assess nonmotor symptoms, we distributed another questionnaire including a Japanese version of each of the following: Geriatric Depression Scale (GDS), Apathy Scale (AS), Pittsburgh Sleep Quality Index (PSQI), (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) Japanese version of the Epworth Sleepiness Scale (JESS), (Takegami et al., 2009) REM sleep Behavior Disorder Screening Questionnaire (RBDSQ), (Stiasny-Kolster et al., 2007) and Parkinson Fatigue Scale (PFS) (Okuma et al., 2009).

2.5 | Information from other assessment batteries

We recorded gender, age at evaluation, age at onset of PD, disease duration, Hoehn and Yahr stage (HY), and a cognitive function battery examined at the same time, including Mini Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005). In relation to MMSE and MoCA, we performed a detailed evaluation by subdomain as shown by Lessig, Nie, Xu, and Corey-Bloom (2012). We also recorded treatment of patients with antiparkinsonian drugs, including levodopa (levodopa/carbidopa, levodopa/benserazide), entacapone, pramipexole, ropinirole, selegiline, amantadine, apomorphine, pergolide, cabergoline, bromocriptine, and rotigotine, on the date of the survey. We converted the total dose of these drugs into a levodopa equivalent daily dose (LEDD) with the formula developed by Tomlinson et al. (2010).

FIGURE 1
Walking route for examining clinically observed freezing of gait
2.6 | Statistical analysis

Continuous variables were checked for normality and homogeneity of variance with Shapiro–Wilk’s and Levene’s tests. Comparisons between groups were analyzed with Kruskal–Wallis tests with post hoc Mann–Whitney U tests. The chi-square test was used to assess associations between categorical variables. Multiple regression analysis adjusted for age at evaluation and sex was performed to elucidate independent factors for the NFOG-Q. We used the stepwise forward method, and the variables that had statistical significance in univariate analysis were chosen. Subjects were grouped into quartiles based on scores on PIGD and PFS. The quartiles for PIGD were <1 (Q1), 1–2 (Q2), 3–5 (Q3), and 6 or more (Q4). The quartiles for PFS were <31 (Q1), 32–46 (Q2), 47–56 (Q3), and 57 or more (Q4). Comparisons between groups were analyzed by Kruskal–Wallis tests with post hoc Mann–Whitney U tests. We used a level of 95% (p < 0.05) as the criterion for statistical significance. Data analysis was conducted with SPSS for Windows, version 20 (Chicago, IL).

3 | RESULTS

3.1 | Patients and classification of FOG

In this study, we enrolled 245 patients with sporadic PD. Ten patients were excluded due to nonreply to the questionnaire, two patients were excluded due to examination refusal, and four patients could not walk. In the end, the sample comprised 229 PD patients. CFOG was observed in 41 patients. In the CFOG group, 20 patients were in the ON state, and four patients were in the OFF state at examination; 17 patients did not have wearing-off symptoms. The most frequent freezing occurred upon turning (27 patients; 66% of objective freezers). Of the patients who did not show CFOG, 101 patients reported FOG on the NFOG-Q, and 87 patients did not (Figure 2). In the SFOG group, 62 patients were in the ON state, and five patients were in the OFF state at examination; 23 patients did not have wearing-off symptoms. The status of 11 patients was unknown.

3.2 | Clinical features of CFOG and SFOG

Demographic features related to FOG are shown in Table 1. According to Kruskal–Wallis tests, we found significant differences in the NFOG-Q, duration of disease, severity of HY stage, UPDRS Part 3 (Rigidity, Akinesia, PIGD), GDS, AS, PSQI, JESS, RBDSQ-J, PFS, MMSE, FAB, MoCA-J, and LEDD. Mann–Whitney tests revealed significant differences in the PD duration, Hoehn–Yahr stage, UPDRS Part 3, Rigidity, Akinesia, PIGD, AS, PSQI, JESS, RBDSQ-J, PFS, MMSE, FAB, MoCA-J, and LEDD between the nonfreezing group and the CFOG group. Significant differences were found in the NFOG-Q, PD duration, HY stage, UPDRS Part 3, Rigidity, PIGD, GDS, PSQI, JESS, PFS, FAB, and LEDD between the nonfreezing group and the SFOG group. Significant differences were found with regard to the NFOG-Q, HY stage, UPDRS Part 3, Akinesia, and PIGD between the CFOG group and the SFOG group (Table 1).

3.3 | Independent predictors for NFOG-Q scores

Multivariate regression analysis revealed that the PIGD, PD duration, and PFS scores were independent predictors of NFOG-Q scores (Table 2).

We also found that the higher the PIGD, the more SFOG and CFOG increased. Post hoc tests related to PIGD revealed significance differences in group distributions between Q1 and the other grades, between Q2 and Q4, and between Q3 and Q4 (Figure 3a). Similarly, the higher the PFS, the more SFOG and CFOG were observed. Post
SAWADA et al.

hoc tests related to PFS revealed significance differences in group distribution between Q1 and Q3, between Q1 and Q4, and between Q2 and Q4 (Figure 3b).

4 | DISCUSSION

We examined features and factors relating to CFOG and SFOG. Among our PD patients, 17.9% (41/229) exhibited CFOG, while 53.7% (101/188) of the remaining PD patients who did not show CFOG during the outpatient clinic were reported to have FOG according to the NFOG-Q. Prevalence of FOG has been reported to range from 47% to 81%, depending on the detection method and the differences in target patient populations (Amboni et al., 2015; J. Hall et al., 2015; J. M. Hall et al., 2014; Macht et al., 2007; Rahman, Griffin, Quinn, & Jahanshahi, 2008; Shine et al., 2012; Snijders et al., 2012). Among these investigations, the prevalence

| TABLE 1 | Descriptive statistics |
|----------|------------------------|
| Variables | Nonfreezer | With SFOG | With CFOG | Kruskal-Wallis test |
| n = 87 | n = 101 | n = 41 | p-value |
| NFOG-Q Median (IQR) | 0 | 14.5 (9.0–20.0)** | 20.0 (15.0–24.0)** | <0.01 |

Demographic factors

| Male:female | Kruskal-Wallis test |
| n | 31:56 | 44:57 | 18:23 | N/A |
| Age (years) Median (IQR) | 71.0 (64.0–78.0) | 71.5 (65.3–76.8) | 75.0 (69.0–80.0) | 0.06 |
| PD duration Median (IQR) | 4.0 (2.0–7.0) | 6.0 (2.0–10.0)** | 10.0 (5.0–15.0)** | <0.01 |

Motor symptoms

| Hoehn-Yahr stage Median (IQR) | 2.0 (1.0–3.0) | 3.0 (2.0–3.0)** | 3.0 (3.0–4.0)** | <0.01 |
| UPDRS Part 3 Median (IQR) | 15.0 (8.0–22.0) | 20.0 (13.25–28.0)** | 26.0 (22.0–34.0)** | <0.01 |
| Tremor Median (IQR) | 1.0 (0.0–2.0) | 0.0 (0.0–2.0) | 1.0 (0.0–2.0) | 0.72 |
| Rigidity Median (IQR) | 4.0 (2.0–5.0) | 5.0 (3.25–7.0)* | 6.0 (3.0–7.0)** | <0.01 |
| Akinesia Median (IQR) | 7.0 (4.0–10.0) | 9.0 (5.0–12.75) | 11.0 (8.0–15.0)** | <0.01 |
| PIGD Median (IQR) | 1.0 (0.0–4.0) | 3.0 (1.0–5.0)** | 8.0 (5.0–9.0)** | <0.01 |

Nonmotor symptoms

| GDS Median (IQR) | 3.5 (1.0–6.0) | 4.0 (2.0–9.0)* | 5.0 (3.0–8.75) | <0.05 |
| AS Median (IQR) | 15.0 (8.0–18.0) | 16.0 (12.75–19.0) | 18.5 (14.0–23.0)* | <0.01 |
| PSQI Median (IQR) | 5.0 (3.0–7.75) | 7.0 (4.0–10.0)* | 7.0 (5.0–10.0)* | <0.01 |
| JESS Median (IQR) | 4.0 (2.0–7.0) | 6.0 (3.0–9.75)* | 6.0 (3.5–12.5)* | <0.05 |
| RBDSQ-J Median (IQR) | 3.0 (1.0–5.0) | 3.0 (2.0–6.0) | 4.0 (2.0–7.0)* | <0.05 |
| PFS Median (IQR) | 36.0 (25.0–49.0) | 49.5 (34.0–61.0)** | 50.0 (42.5–64.0)** | <0.01 |

Cognitive function

| MMSE Median (IQR) | 29.0 (26.0–29.5) | 28.0 (25.0–29.0) | 26.0 (23.0–27.25)** | <0.01 |
| FAB Median (IQR) | 15.0 (13.0–16.0) | 13.5 (11.0–16.0)* | 12.0 (11.0–14.0)* | <0.01 |
| MoCA-J Median (IQR) | 25.0 (22.0–26.0) | 23.0 (10.0–26.0) | 21.0 (24.75)** | <0.05 |
| LEDD (mg) | 271.5 (250.4) | 428.9 (332.2)** | 530.1 (398.6)** | <0.01 |

Note. Statistical analysis was performed as follows; Chi-square test for sex. Kruskal-Wallis tests and Mann-Whitney U test for age, PD duration and LEDD NFOG-Q, Hoehn-Yahr stage, UPDRS Part 3, Tremor, Rigidity, Akinesia, PIGD, GDS, AS, PSQI, JESS, RBDSQ-J, PFS, MMSE, FAB, and MoCA-J. PD: Parkinson’s disease; NFOG-Q: New Freezing of Gait Questionnaire; UPDRS: Unified Parkinson’s Disease Rating Scale; PIGD: postural instability and gait difficulty; LEDD: levodopa equivalent daily dose; GDS: Geriatric Depression Scale; AS: Apathy Scale; PSQI: Pittsburgh Sleep Quality Index; JESS: Japanese version of the Epworth Sleepiness Scale; RBDSQ: REM Sleep Behavior Disorder Screening Questionnaire; PFS: Parkinson Fatigue Scale; MMSE: Mini Mental State Examination; FAB: Frontal Assessment Battery; MoCA: Montreal Cognitive Assessment; SFOG: self-reported FOG; CFOG: clinically observed FOG. N/A: not applicable.

*p < 0.05 and **p < 0.01, Mann-Whitney U test. PD nonfreezing versus SFOG/CFOG; *p < 0.05 and **p < 0.01, Mann-Whitney U test. PD SFOG versus CFOG.

| TABLE 2 | Predictors for SFOG |
|----------|------------------|
| β | p-Value |
| PIGD | 0.41 | <0.01 |
| PD duration | 0.18 | <0.01 |
| PFS | 0.14 | <0.05 |

SFOG: self-reported FOG; PD: Parkinson’s disease; PIGD: postural instability and gait difficulty; PFS: Parkinson Fatigue Scale.
of CFOG via examination was 48%–50% (Shine et al., 2012; Snijders et al., 2012), which was relatively smaller than estimates of SFOG (47%–81%) (Amboni et al., 2015; J. Hall et al., 2015; J. M. Hall et al., 2014; Hely et al., 2008; Macht et al., 2007; Rahman et al., 2008; Shine et al., 2012; Snijders et al., 2012). The prevalence of CFOG in this study was lower than that seen in previous reports. For our outpatients, this may be due to the fact that disease severity in our patients is relatively mild and patients often come to our hospital in the “on” state (Nieuwboer, De Weerdt, Dom, & Lesaffre, 1998). To the best of our knowledge, there is no research that has examined FOG separately (self-reported and clinically observed) like ours. In daily clinical practice, FOG that can be detected in the examination room might be lower compared to previous reports, and a questionnaire might be more useful for the detection of FOG.

FOG was reported to be related to long disease duration, global motor disability due to disease (severity of HY stage, UPDRS Part 3), and nonmotor dysfunctions (apathy, sleepiness, RBD, fatigue, cognitive deficits). Previous studies reported that FOG correlates with UPDRS Part 3, cognition, (Giladi et al., 2001) and RBD (Videnovic et al., 2013). Factors related to CFOG in our study are in agreement with these results. In comparison, we indicated that SFOG is related to a long disease duration, global motor disability due to disease (severity of HY stage, UPDRS Part 3), and nonmotor dysfunctions (depression, sleepiness, fatigue). From these results, there is a possibility that patients in the SFOG group may develop CFOG in the future. This is an important consideration for conducting future longitudinal studies. Accordingly, we think that it is important to properly identify the SFOG group so that interventions that may exacerbate motor or nonmotor symptoms at an inappropriate time are avoided in these patients.

We found that the PIGD, PD duration, and PFS scores were independent predictors of NFOG-Q scores. As the PIGD and PFS became more severe, the proportion of patients with FOG increased. The PIGD disorder and longer duration of disease have been reported previously as risk factors for FOG in PD patients, (Amboni et al., 2015; Giladi et al., 2001) but there is no detailed report on fatigue and FOG as far as we know. Hagell et al. reported an association of fatigue with parkinsonism, (Hagell & Brundin, 2009) especially axial/postural/gait impairment. We previously reported an association between fatigue and gait disturbance in PD patients (Tanaka et al., 2014). There is a report showing that fatigue is related to a disturbance of the serotonergic system in PD patients (Pavese, Metta, Bose, Chaudhuri, & Brooks, 2010). Recently, involvement of nondopaminergic systems, such as the serotonergic system, in FOG of PD patients has been suggested (Devos, Defebvre, & Bordet, 2010; Martens et al., 2016; Takahashi, Tabu, Ozaki, Hamano, & Takeshima, 2019). Taken together with our results, fatigue and FOG in PD patients might be related, and common associated factors might exist. However, both fatigue and FOG occur at high rates as the disease progresses, and causal relationships with fatigue are unclear in our cross-sectional study. Therefore, further longitudinal studies, exploring whether ratings of fatigue are important for the early detection of FOG in PD patients will be needed. Patients with PD with these factors may be cautioned as being at risk of deteriorating FOG.

One major limitation of this study is that a confirmed method for the detection of SFOG in PD patients is not fully established. In the present study, we used the NFOG-Q, a validated questionnaire for FOG in PD with a higher accuracy for detection (Nieuwboer et al., 2009).

5 | CONCLUSION
The frequency of objectively detected FOG is not high, while SFOG might be higher than previously considered. Our study demonstrates that PIGD, longer duration of disease, and fatigue are associated with FOG.

ACKNOWLEDGMENTS
This work was supported by JSPS KAKENHI Grant Number JP17K09799.
CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ORCID

Makoto Sawada https://orcid.org/0000-0003-4143-5791

REFERENCES

Amboni, M., Stocchi, F., Abbuzzese, G., Morgante, L., Onofrj, M., Ruggieri, S., ... Simoni, L. (2015). Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. *Parkinsonism & Related Disorders*, 21, 644–649. https://doi.org/10.1016/j.parkreldis.2015.03.028

Barthel, C., Malila, E., Debou, B., Bloem, B. R., & Ferraye, M. U. (2016). The practicalities of assessing freezing of gait. *Journal of Parkinson's Disease*, 6, 667–674. https://doi.org/10.3233/JPD-160927

Buyssse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research*, 28, 193–213. https://doi.org/10.1016/0165-1781(89)90047-4

Devos, D., Defebvre, L., & Bordet, R. (2010). Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. *Fundamental & Clinical Pharmacology*, 24, 407–421. https://doi.org/10.1111/j.1472-8206.2009.00798.x

Faul, M., Erdfelder, E., Lang, A. E., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39, 175–191. https://www.gpower.hhu.de

Hall, J. M., Hallett, M., & Merello, M. (2008). Freezing of gait: From clinical observation to biological understanding. *Developmental Medicine and Child Neurology*, 50, S6–S9. https://doi.org/10.1111/j.1469-8749.2008.03458.x

Hagell, P., & Bruni, L. (2009). Towards an understanding of fatigue in Parkinson disease. *Journal of Parkinson's Disease*, 5, 1–2. https://doi.org/10.21272/WNL.56.12.1712

Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., & Morris, J. G. (2008). The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. *Movement Disorders*, 23, 837–844. https://doi.org/10.1002/mds.21956

Iseki, K., Fukuyama, H., Oishi, N., Tomimoto, H., Otsuka, Y., Nankaku, M., ... Hanakawa, T. (2015). Freezing of gait and white matter changes: A tract-based spatial statistics study. *Journal of Clinical and Movement Disorders*, 2, 1. https://doi.org/10.1186/s40734-014-0011-2

Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. *The Lancet*, 386, 896–912. https://doi.org/10.1016/s0140-6736(14)61393-3

Lax, M. A., & Caplan, R. B. (2008). The etiology of freezing of gait. *Parkinsonism & Related Disorders*, 14, 307–312. https://doi.org/10.1016/j.parkreldis.2007.10.003

Macht, M., Kaussner, Y., Moller, J. C., Stiasny-Kolster, K., Eggert, K. M., Kruger, H. P., & Ellegirng, H. (2007). Predictors of freezing in Parkinson's disease: A survey of 6,620 patients. *Movement Disorders*, 22, 953–956. https://doi.org/10.1002/mds.21458

Martens, K. A. E., Hall, J. M., Gilat, M., Georgiades, M. J., Walton, C. C., & Lewis, S. J. G. (2016). Anxiety is associated with freezing of gait and attentional set-shifting in Parkinson's disease: A new perspective for early intervention. *Gait & Posture*, 49, 431–436. https://doi.org/10.1016/j.gaitpost.2016.07.182

Nasreddine, Z., Phillips, N., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., ... Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA, a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*, 53, 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Nieuwboer, A., De Weerdt, W., Dom, R., & Lesaffre, E. (1998). A frequency and correlation analysis of motor deficits in Parkinson patients. *Disability and Rehabilitation*, 20, 142–150. https://doi.org/10.1080/09638289809166074

Nieuwboer, A., Rochester, L., Herman, T., Vandenberghhe, W., Emil, G. E., Thomaes, T., & Giladi, N. (2009). Reliability of the new freezing of gait questionnaire: Agreement between patients with Parkinson's disease and their carers. *Gait & Posture*, 30, 459–463. https://doi.org/10.1016/j.gaitpost.2009.07.108

Nutt, J. G., Bloem, B. R., Giladi, N., Hallett, M., Horak, F. B., & Nieuwboer, A. (2011). Freezing of gait: Moving forward on a mysterious clinical phenomenon. *The Lancet Neurology*, 10, 734–744. https://doi.org/10.1016/s1474-4422(11)70143-0

Okuma, Y. (2014). Practical approach to freezing of gait in Parkinson's disease. *Practical Neurology*, 14, 222–230. https://doi.org/10.1136/practneur-2013-000743

Okuma, Y., Kamei, S., Morita, A., Yoshii, F., Yamamoto, T., Hashimoto, S., ... Hirata, K. (2009). Fatigue in Japanese patients with Parkinson's disease: A study using Parkinson Fatigue Scale. *Movement Disorders*, 24, 1977–1983. https://doi.org/10.1002/mds.22731

Okuma, Y., Silvade Lima, A. L., Fukae, J., Bloem, B. R., & Snijders, A. H. (2018). A tract-based spatial statistics study. *Movement Disorders*, 33, 3434–3443. https://doi.org/10.1001093/brain/aws268

Rahman, S., Griffin, H., Quinn, N., & Jahanshahi, M. (2008). The factors that induce or overcome freezing of gait in Parkinson’s disease. *Behavioural Neurology*, 19, 127–136. https://doi.org/10.1155/2008/456298

Schaafsma, J. D., Balash, Y., Gurevich, T., Bartels, A. L., Haasdoeff, J. M., & Giladi, N. (2003). Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. *European Journal of Neurology*, 10, 391–398. https://doi.org/10.1046/j.1468-1331.2003.00611.x

Shine, J. M., Moore, S. T., Bolitho, S. J., Morris, T. R., Dilda, V., Naismith, S. L., & Lewis, S. J. (2012). Assessing the utility of Freezing of Gait Questionnaires in Parkinson's disease. *Parkinsonism & Related Disorders*, 18(1), 25–29. https://doi.org/10.1016/j.parkreldis.2011.08.002

Silva de Lima, A. L., Evers, L. J. W., Hahn, T., Bataille, L., Hamilton, J. L., Little, M. A., ... Faber, M. J. (2017). Freezing of gait and fall detection in Parkinson's disease using wearable sensors: A systematic review. *Journal of Neurology*, 264, 1642–1654. https://doi.org/10.1007/s00415-017-8424-0

Snijders, A. H., Haaxma, C. A., Hagen, Y. J., Munneke, M., & Bloem, B. R. (2012). Freezer or non-freezer: Clinical assessment of freezing of gait. *Parkinsonism & Related Disorders*, 18, 149–154. https://doi.org/10.1016/j.parkreldis.2011.09.006

Snijders, A. H., Takakusaki, K., Debou, B., Lozano, A. M., Krishna, V., Fasano, A., ... Hallett, M. (2016). Physiology of freezing of gait. *Annals of Neurology*, 80, 644–659. https://doi.org/10.1002/ana.24778

Stiasny-Kolster, K., Mayer, G., Schafer, S., Moller, J. C., Heinzel, Gutenbrunner, M., & Oertel, W. H. (2007). The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. *Movement Disorders*, 22, 2386–2393. https://doi.org/10.1002/mds.21740

Takahashi, M., Tabu, H., Ozaki, A., Hamano, T., & Takeshima, T. (2019). Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: A multicenter randomized
study. *Internal Medicine*, 58, 361–368. https://doi.org/10.2169/internalmedicine.1359-18
Takegami, M., Suzukamo, Y., Wakita, T., Noguchi, H., Chin, K., Kadotani, H., ... Fukuhara, S. (2009). Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. *Sleep Medicine*, 10, 556–565. https://doi.org/10.1016/j.sleep.2008.04.015
Tanaka, K., Wada-Isoe, K., Yamamoto, M., Tagashira, S., Tajiri, Y., Nakashita, S., & Nakashima, K. (2014). Clinical evaluation of fatigue in Japanese patients with Parkinson's disease. *Brain and Behavior*, 4, 643–649. https://doi.org/10.1002/brb3.247
Teramoto, H., Morita, A., Ninomiya, S., Shiota, H., & Kamei, S. (2014). Relation between freezing of gait and frontal function in Parkinson's disease. *Parkinsonism & Related Disorders*, 20, 1046–1049. https://doi.org/10.1016/j.parkreldis.2014.06.022
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Movement Disorders*, 25, 2649–2653. https://doi.org/10.1002/mds.23429
Videnovic, A., Marlin, C., Alibiglou, L., Planetta, P., Vaillancourt, D., & Mackinnon, C. (2013). Increased REM sleep without atonia in Parkinson disease with freezing of gait. *Neurology*, 81, 1030–1035. https://doi.org/10.1212/WNL.0b013e3182a4a408
Zuo, L. J., Piao, Y. S., Li, L. X., Yu, S. Y., Guo, P., Hu, Y., ... Zhang, W. (2017). Phenotype of postural instability/gait difficulty in Parkinson disease: Relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. *Scientific Reports*, 7, 44872. https://doi.org/10.1038/srep44872

How to cite this article: Sawada M, Wada-Isoe K, Hanajima R, Nakashima K. Clinical features of freezing of gait in Parkinson’s disease patients. *Brain Behav*. 2019;9:e01244. https://doi.org/10.1002/brb3.1244